Posted by Michael Wonder on 30 Apr 2021
Ilaris receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease
29 April 2021 - The approval of Ilaris (canakinumab) in the treatment of adult-onset Still's disease brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
Novartis Pharmaceuticals Canada is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still's disease, including adult-onset Still's disease.
